Thomas Katharine, Voros Brianne A, Meadows-Taylor Meghan, Smeltzer Matthew P, Griffin Ryan, Boudreaux J Philip, Thiagarajan Ramcharan, Woltering Eugene A, Ramirez Robert A
Division of Hematology/Oncology, Louisiana State University Health Science Center, New Orleans, LA 70112, USA.
Department of Surgery, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.
Cancers (Basel). 2020 Jan 14;12(1):206. doi: 10.3390/cancers12010206.
Capecitabine and temozolomide (CAPTEM) have shown promising results in the treatment of neuroendocrine neoplasms (NEN). The aim of this study was to evaluate the outcome and role for CAPTEM in malignant neuroendocrine neoplasms. Data were obtained from NEN patients who received at least one cycle of CAPTEM between November 2010 and June 2018. The average number of cycles was 9.5. For analysis, 116 patients were included, of which 105 patients (91%) underwent prior treatment. Median progression free survival (PFS) and overall survival (OS) were 13 and 38 months, respectively. Overall response rate (ORR) was 21%. Disease control rate (DCR) was 73% in all patients. PFS, median OS, ORR, and DCR for pancreatic NENs (pNEN) vs. non-pNEN was 29 vs. 11 months, 35 vs. 38 months, 38% vs. 9%, and 77% vs. 71%, respectively. Patients with pNEN had a 50% lower hazard of disease progression compared to those with non-pNEN (adjusted Hazard Ratio: 0.498, = 0.0100). A significant difference in PFS was found between Ki-67 < 3%, Ki-67 3-20%, Ki-67 > 20-54%, and Ki-67 ≥ 55% (29 vs. 12 vs. 7 vs. 5 months; = 0.0287). Adverse events occurred in 74 patients (64%). Our results indicate that CAPTEM is associated with encouraging PFS, OS, and ORR data in patients with NENs.
卡培他滨和替莫唑胺（CAPTEM）在神经内分泌肿瘤（NEN）治疗中已显示出有前景的结果。本研究的目的是评估CAPTEM在恶性神经内分泌肿瘤中的疗效及作用。数据来源于2010年11月至2018年6月期间接受至少一个周期CAPTEM治疗的NEN患者。平均周期数为9.5个。分析纳入了116例患者，其中105例患者（91%）曾接受过先前治疗。中位无进展生存期（PFS）和总生存期（OS）分别为13个月和38个月。总缓解率（ORR）为21%。所有患者的疾病控制率（DCR）为73%。胰腺神经内分泌肿瘤（pNEN）与非pNEN的PFS、中位OS、ORR和DCR分别为29个月对11个月、35个月对38个月、38%对9%、77%对71%。与非pNEN患者相比，pNEN患者疾病进展风险低50%（校正风险比：0.498，P = 0.0100）。在Ki-67＜3%、Ki-67 3-20%、Ki-67＞20-54%和Ki-67≥55%的患者之间发现PFS存在显著差异（29个月对12个月对7个月对5个月；P = 0.0287）。74例患者（64%）发生了不良事件。我们的结果表明，CAPTEM与NEN患者令人鼓舞的PFS、OS和ORR数据相关。
